Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 2;3(2):11. doi: 10.3390/epigenomes3020011

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Histone acetyltransferase (HAT) inhibitors influence the acetylation levels at super-enhancers. (A) Scatterplot displaying the differential enrichment of H3K27ac (log2 ChIP-seq read count) for ICG-001 (left) and C646 (right) compared to control; the blue diagonal line separates those of increasing or decreasing signals with the colored dots corresponding to regions with significant changes in treatment compared to control (FDR < 0.1). (B) Overlap analysis of regions comparing the increased or decreased H3K27ac regions after ICG-001 and C646 treatment. (C) Boxplots displaying log2 fold change of genes (treatment vs. control) within the given differential domains identified in (A) (Welch’s t-test, * represents p < 0.05). (D) Pathway enrichment analysis of genes within altered super-enhancers after ICG-001 or C646 treatment.